Attached files
file | filename |
---|---|
EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - PROLUNG INC | f10qa093012_ex32z1.htm |
EX-32.2 - EXHIBIT 32.2 SECTION 906 CERTIFICATION - PROLUNG INC | f10qa093012_ex32z2.htm |
EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - PROLUNG INC | f10qa093012_ex31z1.htm |
EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATION - PROLUNG INC | f10qa093012_ex31z2.htm |
EXCEL - IDEA: XBRL DOCUMENT - PROLUNG INC | Financial_Report.xls |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q/A
Amendment No. 1
X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2012
. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 000-54600
FRESH MEDICAL LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 20-1922768 |
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification No.) |
757 East South Temple, Suite 150 |
|
|
Salt Lake City, Utah |
| 84102 |
(Address of principal executive offices) |
| (Zip Code) |
(801) 7360729
(Registrants telephone number, including area code)
Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X . No .
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes X . No .
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Ruble 12b-2 of the Exchange Act.
Large accelerated filer | . | Accelerated filer | . |
Non-accelerated filer | . (Do not check if a smaller reporting company) | Smaller reporting company | X . |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes . No X .
The number of shares of Common Stock, $0.001 par value, outstanding on November 1, 2012 was 11,094,718.
FRESH MEDICAL LABORATORIES, INC.
Explanatory Note
This Amendment No. 1 on Form 10-Q/A amends the registrants Quarterly Report on Form 10-Q for the quarterly period ending September 30, 2012 as filed with the Securities and Exchange Commission by the registrant on November 19, 2012. This Amendment is filed to include the 101 XBRL Interactive Data File exhibits required by Item 6. No other items are being amended except as described in this Explanatory Note and this Amendment does not reflect any events occurring after the filing of the original Quarterly Report on Form 10-Q for the period ending September 30, 2012.
PART II--OTHER INFORMATION
ITEM 6. EXHIBITS.
|
|
Exhibit Number | Description |
31.1 | Certification of Chief Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 | Certification of Chief Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1 | Certification of Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2 | Certification of Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101* | XBRL (eXtensible Business Reporting Language) |
*XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
FRESH MEDICAL LABORATORIES, INC.
(Registrant)
By:
/s/ Steven C. Eror
Steven C. Eror
Chief Executive Officer, President, and Director
(Principal Executive Officer)
Date: November 26, 2012
By:
/s/ Steven C. Eror
Steven C. Eror
Acting Chief Financial Officer
(Acting Principal Financial and Accounting Officer)
Date: November 26, 2012